TY - JOUR T1 - Age-Sex based estimates of risk of death from COVID Infection in Adult Cancer Patients JF - medRxiv DO - 10.1101/2020.03.18.20038067 SP - 2020.03.18.20038067 AU - Matt Williams AU - Ella Mi AU - Kerlann Le Calvez AU - Jiarong Chen AU - Lillie Pakzad-Shahabi AU - Seema Dadhania AU - James Wang AU - Andrew L.K.Ho AU - Simon Rabinowicz Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/19/2020.03.18.20038067.abstract N2 - Background During the coronavirus disease 2019 (COVID) pandemic, various organisations have produced management guidance for cancer patients and the delivery of cytotoxic chemotherapy, but none offer estimates of risk, or the potential impact across populations.Methods We combine data from four countries to produce pooled age-banded Case Fatality Rates (CFRs), calculate the sex-difference in survival and use data from four recent studies to convert CFRs into age-sex stratified Infection Fatality Rates (IFRs). We estimate the additional risk of death in cancer patients, and in those receiving chemotherapy. We illustrate the impact of these by considering the impact on a national incident cancer cohort and present some clinical scenarios.Results We obtained data based on 412,985 cases and 41,854 deaths. The pooled estimate for IFR was 0.92%. Age-related IFRs for patients with cancer range from 0.01% to 29%, and higher in patients receiving chemotherapy. The risk is significantly higher in men than women. 40% of all male and 32% of all female patients with a new diagnosis of cancer this year have an IFR of ≥ 5%.Conclusions Older male patients are at a higher risk of death with COVID infection. Patients with cancer are also at higher risk, as are those who have recently received chemotherapy. We provide well-founded estimates to allow patients and clinicians to better balance these risks, and illustrate the wider impact in a national incident cohort.FUNDING & DISCLOSURES MW receives funding from the Imperial/ NIHR BRC; SD receives funding from the IC/ICR CRUK Major Centre; LPS receives funding from Brain Tumour Research and the Brain Tumour Research Campaign. JC is supported by the Guangdong International Young Research Talents Training Programme for Postdoctoral Researchers. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Code, data and appendicies are available at: https://gitlab.com/computational.oncology/covidcancerriskHIGHLIGHTSWe report case and infection fatality rates based on a large multi-national cohortWe provide sex and age-specific estimates of riskWe provide estimates of additional risk for patients with cancer to allow patients and clinicians to balance risk and benefitCompeting Interest StatementThe authors have declared no competing interest.Funding StatementMW receives funding from the Imperial/ NIHR BRC; SD receives funding from the IC/ICR CRUK Major Centre; LPS receives funding from Brain Tumour Research and the Brain Tumour Research Campaign. JC is supported by the Guangdong International Young Research Talents Training Programme for Postdoctoral Researchers.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesReaders can explore data and appendicies at https://gitlab.com/computational.oncology/covidcancerrisk https://gitlab.com/computational.oncology/covidcancerrisk ER -